Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SBIO, a biotech company focused on the research and clinical development, has restructured its collaboration and option agreement to regain North American and European rights to its novel JAK2 inhibitors - SB1518 and SB1578 from Onyx Pharmaceuticals.
Subscribe to our email newsletter
As a result of this, SBIO can now independently drive the development of its lead JAK2 program.
Recent data from phase 2 clinical trials of SB1518 indicated promising clinical efficacy and good tolerability for the treatment of myelofibrosis (MF), an orphan indication with high unmet medical need.
SB1518 has also demonstrated clinical benefits in patients with relapsed/refractory lymphoma.
SBIO plans to advance SB1518 and SB1578 through clinical development, with pivotal trials for SB1518 anticipated to begin later this year.
SBIO CEO Jan-Anders Karlsson said SB1518 has now reached a critical inflection point where its future success in a highly competitive field depends on an aggressive and focused development plan.
"As an existing shareholder, Onyx’s interests remain aligned with SBIO’s objective to maximize the value of the JAK2 program and to share in the upside potential of SB1518 and other SBIO assets," Karlsson said.